Ascletis Pharma-B (01672.HK): Ascletis to Present Research Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Agonist Peptide ASC37 at ObesityWeek 2026

Zhitong Finance APP News, Ascletis Pharma-B (01672.HK) announced that two posters on its obesity pipelinethe oral small molecule GIPR agonist ASC48 and the GLP-1R/GIPR/GCGR triple agonist peptide ASC37will be presented at ObesityWeek 2026. The conference will be held from November 14 to 17, 2026 in Washington, D.C., USA.